Abstract 522P
Background
The standard treatment of relapsed small cell lung cancer (SCLC) has not been established yet, and weekly paclitaxel (PTX) is recommend as one of the treatment options for relapsed SCLC. In advanced non-small cell lung cancer, nanoparticle albumin-bound paclitaxel (nab-PTX) has shown equal activity to PTX with less neurological adverse event. However, the benefit of nab-PTX for relapsed SCLC has not been fully evaluated yet. The aim of this study is to evaluate efficacy and safety of both weekly nab-PTX and weekly PTX regimen for relapsed SCLC.
Methods
We retrospectively reviewed consecutive relapsed SCLC patients who were treated with weekly nab-PTX (80mg/m2, day1,8,15/q4 weeks) or weekly PTX (80mg/m2, day1,8,15,22/q4 weeks) at Tosei general hospital, from January 2008 to March 2019. We evaluated the objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS) and adverse event profile in each regimen.
Results
A total of 52 patients with relapsed SCLC were reviewed, 18 and 34 patients received weekly nab-PTX (group A) and weekly PTX (group B), respectively. Patient characteristics (group A: group B) were as follows; male 17 (94%): 28(82%), median of age 74 :70, ECOG-PS 0-1 18(100%) :29(85%), extensive disease 14(78%) :17(50%), refractory relapse 16(89%) :20(59%). ORR in group A and B were 5.6% and 8.8%, and DCR in group A and B were 55.6% and 38%, respectively. The PFS and OS had no difference between group A and B (median PFS, 3.2months and 1.7months; median OS, 5.4 months and 4.5months). Toxicity profile of group A was tolerable as well as group B. About neurological adverse event, group A had less toxicity than group B in any grade (5(28%) and 12(35%) patients) but no severe adverse event was observed.
Conclusions
Weekly nab-PTX and weekly PTX showed similar efficacy for relapsed SCLC. In terms of toxicity, weekly nab-PTX might be less toxic especially in neurological adverse event. Although this is a retrospective single center study, the nab-PTX might be a treatment option for relapsed SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hajime Oi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract